Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

Also called NCT03574311

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03574311
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Finland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03574311. Randomized; triple masking; primary purpose prevention. Start 2018-10-02 (actual); primary completion 2022-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery
Acronym
PREFER-CABG
Condition
Postoperative Complications
Condition
Aortic Valve Stenosis
Condition
Mitral Valve Disease
Condition
Aortic Aneurysm, Thoracic
Intervention (Drug)
Ferric carboxymaltose
Intervention (Other)
Physiological saline
Lead sponsor
Turku University Hospital (class: other government)
Collaborator
Vifor Pharma (class: industry)

Record details

Record id
cardio:ct-nct03574311
Content hash
fcda3621ae0c12c2feaf270f9faac9fd8501692f4c06a052913abc92f0454b6a